-
公开(公告)号：US09284543B2
公开(公告)日：2016-03-15
申请号：US13385527
申请日：2012-02-21
CPC分类号： C12N9/2408 , A61K38/00 , A61K47/60 , A61K47/61 , A61K47/6435 , C12N9/2474
摘要： Soluble PH20 polypeptides are provided, including extended soluble PH20 polypeptides, and uses thereof. Also provided are other C-terminally truncated PH20 polypeptides and partially deglycosylated PH20 polypeptides and uses thereof.
摘要翻译： 提供可溶性PH20多肽，包括延长的可溶性PH20多肽及其应用。 还提供了其它C末端截短的PH20多肽和部分去糖基化的PH20多肽及其用途。
-
公开(公告)号：US20130101577A9
公开(公告)日：2013-04-25
申请号：US13385527
申请日：2012-02-21
IPC分类号： A61K38/47 , C12N9/96 , C12N15/63 , C12N5/10 , C12N1/21 , C12N1/19 , C12N1/15 , C12N15/56 , A61P25/00 , A61P35/00 , A61P27/02 , A61P9/00 , A61P29/00 , A61P9/12 , A61P31/10 , A61P33/04 , A61P31/00 , A61P25/16 , A61K39/395 , A61P33/06 , C12N9/26
CPC分类号： C12N9/2408 , A61K38/00 , A61K47/60 , A61K47/61 , A61K47/6435 , C12N9/2474
摘要： Soluble PH20 polypeptides are provided, including extended soluble PH20 polypeptides, and uses thereof. Also provided are other C-terminally truncated PH20 polypeptides and partially deglycosylated PH20 polypeptides and uses thereof.
摘要翻译： 提供可溶性PH20多肽，包括延长的可溶性PH20多肽及其应用。 还提供了其它C末端截短的PH20多肽和部分去糖基化的PH20多肽及其用途。
-
公开(公告)号：US20120213767A1
公开(公告)日：2012-08-23
申请号：US13385527
申请日：2012-02-21
IPC分类号： A61K38/47 , C12N9/96 , C12N15/63 , C12N5/10 , C12N1/21 , C12N1/19 , C12N1/15 , C12N15/56 , A61P25/00 , A61P35/00 , A61P27/02 , A61P9/00 , A61P29/00 , A61P9/12 , A61P31/10 , A61P33/04 , A61P31/00 , A61P25/16 , A61K39/395 , A61P33/06 , C12N9/26
CPC分类号： C12N9/2408 , A61K38/00 , A61K47/60 , A61K47/61 , A61K47/6435 , C12N9/2474
摘要： Soluble PH20 polypeptides are provided, including extended soluble PH20 polypeptides, and uses thereof. Also provided are other C-terminally truncated PH20 polypeptides and partially deglycosylated PH20 polypeptides and uses thereof.
摘要翻译： 提供可溶性PH20多肽，包括延长的可溶性PH20多肽及其应用。 还提供了其它C末端截短的PH20多肽和部分去糖基化的PH20多肽及其用途。
-
公开(公告)号：US08927249B2
公开(公告)日：2015-01-06
申请号：US12653245
申请日：2009-12-09
CPC分类号： C12N9/2408 , A61K38/00 , A61K47/60 , A61K47/61 , A61K47/6435 , C12N9/2474
摘要： Soluble PH20 polypeptides are provided, including extended soluble PH20 polypeptides, and uses thereof. Also provided are other C-terminally truncated PH20 polypeptides and partially deglycosylated PH20 polypeptides and uses thereof.
摘要翻译： 提供可溶性PH20多肽，包括延长的可溶性PH20多肽及其应用。 还提供了其它C末端截短的PH20多肽和部分去糖基化的PH20多肽及其用途。
-
公开(公告)号：US20100143457A1
公开(公告)日：2010-06-10
申请号：US12653245
申请日：2009-12-09
IPC分类号： A61K38/47 , C12N9/26 , C12N9/96 , C07H21/04 , C12N15/63 , C12N5/10 , A61K39/395 , A61K9/127 , A61K38/20 , A61K38/21 , A61P35/00
CPC分类号： C12N9/2408 , A61K38/00 , A61K47/60 , A61K47/61 , A61K47/6435 , C12N9/2474
摘要： Soluble PH20 polypeptides are provided, including extended soluble PH20 polypeptides, and uses thereof. Also provided are other C-terminally truncated PH20 polypeptides and partially deglycosylated PH20 polypeptides and uses thereof.
摘要翻译： 提供可溶性PH20多肽，包括延长的可溶性PH20多肽及其应用。 还提供了其它C末端截短的PH20多肽和部分去糖基化的PH20多肽及其用途。
-
6.发明申请Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof 审中-公开有条件的活性抗表皮生长因子受体抗体及其使用方法公开(公告)号：US20130266579A1
公开(公告)日：2013-10-10
申请号：US13815553
申请日：2013-03-08
IPC分类号： C07K16/28
CPC分类号： C07K16/2863 , A61K39/39558 , A61K47/6825 , A61K47/6849 , A61K47/6851 , A61K2039/505 , C07K16/30 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/92 , A61K39/00
摘要： Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies.
摘要翻译： 本文提供了修饰的抗EGFR抗体和编码修饰的抗EGFR抗体的核酸分子。 还提供了使用修饰的抗EGFR抗体的治疗和使用的方法。
-
7.发明申请MODIFIED ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF 审中-公开抗变性抗生殖因子受体抗体的修饰及其使用方法公开(公告)号：US20150071923A1
公开(公告)日：2015-03-12
申请号：US14485620
申请日：2014-09-12
CPC分类号： C07K16/2863 , A61K47/6803 , A61K47/6855 , A61K47/6877 , C07K16/30 , C07K16/3015 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/624 , C07K2317/626 , C07K2317/76 , C07K2317/92
摘要： Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies.
摘要翻译： 本文提供了修饰的抗EGFR抗体和编码修饰的抗EGFR抗体的核酸分子。 还提供了使用修饰的抗EGFR抗体的治疗和使用的方法。
-
8.发明申请Methods for assessing and identifying or evolving conditionally active therapeutic proteins 有权用于评估和鉴定或发展有条件活性的治疗性蛋白质的方法公开(公告)号：US20120108455A1
公开(公告)日：2012-05-03
申请号：US13200666
申请日：2011-09-27
申请人： Lalitha Kodandapani , Louis H. Bookbinder , Gregory I. Frost , Philip Lee Sheridan , Harold Michael Shepard , Ge Wei , Lei Huang
发明人： Lalitha Kodandapani , Louis H. Bookbinder , Gregory I. Frost , Philip Lee Sheridan , Harold Michael Shepard , Ge Wei , Lei Huang
CPC分类号： G01N33/5011 , C07K16/2863 , C07K16/30 , C07K16/44 , C07K2317/34 , G01N33/5014 , G01N33/5088 , G01N33/53 , G01N2333/71
摘要： Methods for evolving or selecting or producing therapeutic proteins that exhibit reduced adverse side-effects and the resulting proteins are provided. For example, provided herein is an in vitro assay to identify conditionally active therapeutic proteins that exhibit better activity within one in vivo environment compared to another in vivo environment. The methods include the steps of a) testing the activity of a protein under conditions in which normal or increased activity is desired; b) testing the activity of the protein under conditions in which reduced activity compared to normal is desired; and c) comparing the activity in a) with b) and selecting/identifying a protein that has greater activity in a) compared to b). The selected/identified protein is a conditionally active protein.
摘要翻译： 提供了演变或选择或产生表现出减少的副作用减轻的所得蛋白质的方法。 例如，本文提供了一种体外测定法，用于鉴定在体内环境中与另一体内环境相比表现出更好活性的条件活性治疗性蛋白质。 所述方法包括以下步骤：a）在需要正常或增加活性的条件下测试蛋白质的活性; b）在需要降低活性的条件下测试蛋白质的活性; 和c）比较a）中的活性和b）和选择/鉴定在a）中比b）具有更大活性的蛋白质。 所选择/鉴定的蛋白质是有条件活性蛋白质。
-
9.发明授权公开(公告)号：US09683985B2
公开(公告)日：2017-06-20
申请号：US13200666
申请日：2011-09-27
申请人： Lalitha Kodandapani , Louis H. Bookbinder , Gregory I. Frost , Philip Lee Sheridan , Harold Michael Shepard , Ge Wei , Lei Huang
发明人： Lalitha Kodandapani , Louis H. Bookbinder , Gregory I. Frost , Philip Lee Sheridan , Harold Michael Shepard , Ge Wei , Lei Huang
CPC分类号： G01N33/5011 , C07K16/2863 , C07K16/30 , C07K16/44 , C07K2317/34 , G01N33/5014 , G01N33/5088 , G01N33/53 , G01N2333/71
摘要： Methods for evolving or selecting or producing therapeutic proteins that exhibit reduced adverse side-effects and the resulting proteins are provided. For example, provided herein is an in vitro assay to identify conditionally active therapeutic proteins that exhibit better activity within one in vivo environment compared to another in vivo environment. The methods include the steps of a) testing the activity of a protein under conditions in which normal or increased activity is desired; b) testing the activity of the protein under conditions in which reduced activity compared to normal is desired; and c) comparing the activity in a) with b) and selecting/identifying a protein that has greater activity in a) compared to b). The selected/identified protein is a conditionally active protein.
-
10.发明申请Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof 审中-公开有条件的活性抗表皮生长因子受体抗体及其使用方法公开(公告)号：US20140170159A9
公开(公告)日：2014-06-19
申请号：US13815553
申请日：2013-03-08
IPC分类号： C07K16/28
CPC分类号： C07K16/2863 , A61K39/39558 , A61K47/6825 , A61K47/6849 , A61K47/6851 , A61K2039/505 , C07K16/30 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/92 , A61K39/00
摘要： Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies.
摘要翻译： 本文提供了修饰的抗EGFR抗体和编码修饰的抗EGFR抗体的核酸分子。 还提供了使用修饰的抗EGFR抗体的治疗和使用的方法。
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.062 秒)
